Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

GLYC - GLYCOMIMETICS INC

IEX Last Trade
0.2338
-0.013   -5.389%

Share volume: 0
Last Updated: Fri 27 Dec 2024 06:26:42 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.40%

PREVIOUS CLOSE
CHG
CHG%
$0.25
-0.01
-5.11%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
25%
Profitability 25%
Dept financing 2%
Liquidity 50%
Performance 25%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
11.78%
1 Month
-24.61%
3 Months
41.94%
6 Months
-16.55%
1 Year
-90.40%
2 Year
-89.34%
Key data
Stock price
$0.23
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.15 - $3.53
52 WEEK CHANGE
-$90.36
MARKET CAP 
11.369 M
YIELD 
N/A
SHARES OUTSTANDING 
64.484 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/01/2024
BETA 
0.95
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$688,887
AVERAGE 30 VOLUME 
$762,484
Company detail
CEO: Harout Semerjian
Region: US
Website: glycomimetics.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

GlycoMimetics, Inc. focuses on the discovery and development of novel glycomimetic drugs. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML.

Recent news